The FDA’s recent announcement on real-time clinical trials (RTCTs) may represent one of the most significant shifts in clinical development and regulatory engagement in years. Through two proof-of-concept programs and a broader pilot initiative now under consideration, the agency is signaling a move toward more continuous visibility into clinical trial data, safety signals, and efficacy trends during study conduct rather than after the fact.
If confirmed, this model could fundamentally reshape how sponsors (together with CROs) design, monitor, adapt, and ultimately submit clinical studies for regulatory review. It also raises important operational, statistical, and regulatory questions that the industry will need to address quickly.
The implications extend far beyond technology. This is about changing the cadence of interaction between sponsors and regulators, changing how evidence is evaluated during development, and potentially changing the pace and structure of NDA and BLA review itself.
On April 28, 2026, FDA announced two proof-of-concept real-time clinical trial programs involving AstraZeneca and Amgen, alongside a Request for Information (RFI) for a broader pilot program.
The initial proof-of-concept studies include:
According to FDA, the agency has already received and validated real-time trial signals from AstraZeneca’s study through a technical framework developed with Paradigm Health, demonstrating that secure data transmission and regulatory review workflows are technically feasible.
FDA also issued an RFI seeking industry input on operational, technical, and regulatory considerations for scaling the model into a broader pilot program later this year.
While these initiatives are still early, the direction is clear: FDA is exploring a future in which regulators may have more continuous visibility into emerging trial data throughout study conduct to accelerate regulatory review timelines and to reduce risks during this NDA review.
Historically, clinical development has operated through structured milestones and periodic regulatory interactions. Sponsors conduct the study, monitor safety internally, perform predefined analyses, and ultimately submit findings to regulators at designated checkpoints.
The RTCT model introduces the possibility of a more dynamic and continuous regulatory relationship. In principle, this could be a major positive step forward for both sponsors and regulators.
Earlier FDA visibility into safety and efficacy trends could:
For high-risk or high-cost programs, earlier insight could prevent sponsors from continuing studies that are unlikely to succeed or require major redesign. Conversely, strong early signals could help promising therapies move more efficiently through development with the risks to put on hold some studies for uneven safety reasons.
This also appears to reflect lessons reinforced during the COVID-19 era, when rapid evidence review, ongoing sponsor-agency communication, and accelerated decision-making became central to quick vaccine and therapeutic approvals. The RTCT initiative seems to extend that philosophy into a more permanent operational framework.
However, moving from episodic review to real-time oversight introduces a completely new layer of complexity.
One of the most immediate questions is whether FDA has the operational capacity to support real-time clinical trial oversight at scale.
Continuous or near-continuous access to trial data creates expectations around responsiveness, interpretation, and regulatory feedback. That raises several practical considerations:
Real-time access must not become real-time bottlenecking.
For RTCT to work effectively, FDA and sponsors will likely need to proactively define clear governance structures around:
Without those guardrails, continuous oversight could create uncertainty rather than efficiency.
A Potential Shift in Trial Conduct and Endpoint Assessment
Another major implication is how this model interacts with longstanding principles around trial integrity and endpoint assessment.
Traditionally, interim analyses and endpoint evaluations are tightly controlled to avoid introducing operational bias or compromising study validity. Access to evolving efficacy data during trial conduct has historically been highly restricted. The RTCT framework challenges some of those conventions.
If regulators are monitoring emerging endpoints and safety trends in real time, sponsors may face new decisions about:
This could lead to more protocol amendments and more adaptive study designs. In some cases, that flexibility may improve study quality and reduce downstream regulatory risk. In others, it could extend timelines, increase operational burden, and complicate statistical interpretation. The key challenge will be balancing responsiveness with scientific discipline.
A real-time trial model cannot become an improvised trial model.
Sponsors participating in RTCT programs will likely need:
Another important consideration is how other regulatory agencies will view this model.
If FDA becomes more actively involved during study conduct — potentially guiding endpoint interpretation, safety monitoring approaches, or protocol evolution — sponsors running global development programs may need to consider whether other regulators will view those trials differently.
Questions remain around:
This is especially important for global oncology, rare disease, and imaging-heavy studies where multinational enrollment is common.
Alignment with FDA is valuable, but sponsors cannot afford to optimize exclusively for one regulator if broader global acceptance becomes more complicated.
The operational burden associated with RTCTs may ultimately fall most heavily on data infrastructure and study operations.
Real-time or near-real-time regulatory visibility requires:
The challenge becomes even more significant when imaging, biomarkers, wearable data, or EHR-derived information are involved. Questions the industry will need to answer include:
Many organizations still struggle with fragmented systems, delayed data reconciliation, and inconsistent interoperability across study partners. RTCTs may expose those weaknesses quickly. Acceleration of processes cannot compromise quality of the data which remains pivotal for any drug approval.
The sponsors best positioned for this future will likely be those that already view data operations as a strategic capability rather than an administrative function.
For imaging-heavy trials, the implications are particularly significant. Imaging endpoints are often among the most operationally complex components of a study. They involve:
If imaging data become part of a real-time regulatory monitoring framework, the need for operational rigor will increase substantially.
Sponsors may need:
Similarly, safety monitoring could evolve toward more integrated and continuous signal detection across imaging, laboratory, clinical, and biomarker data streams.
Real-time visibility does not reduce the need for rigor. It increases the need for operational consistency and endpoint discipline.
Even though the RTCT initiative is still in its early stages, sponsors, CROs, and clinical technology providers should begin evaluating what this model could mean for future programs.
Organizations should be asking:
The FDA’s broader pilot program may initially involve a limited number of organizations, but the concepts behind RTCTs are unlikely to remain confined to a small pilot environment for long.
FDA’s real-time clinical trials initiative could become a transformative development for clinical research and regulatory review.
Earlier visibility into emerging evidence may help sponsors make better decisions, identify risks sooner, improve alignment with regulators, and potentially accelerate development timelines. For patients, that could ultimately translate into more efficient access to effective therapies.
But the success of this model will depend on far more than AI tools or faster dashboards.
It will require:
The industry is entering a period where the distinction between trial conduct and regulatory review may begin to blur.
At the time clinical study preparation and execution is under a major transformation with AI, this new transformative shift implies that organizations that prepare early for that shift will likely be in the strongest position as real-time clinical development evolves from proof-of-concept into broader practice.